GLOBUS MEDICAL INC
$72.14
−0.16 (−0.22%) · delayed · Nov 13, 2026
Five-year price
52w $70.40 to $101.40
- Market cap
- $9.7B
- Enterprise value
- $9.2B
- P/E
- 18.4×
- 37.7× on 3y avg EPS
- EV / EBIT
- 19.1×
- FCF yield
- 6.1%
- ROIC
- 10.5%
- Debt / equity
- —
- Piotroski F
- 8/9
Value scorecard · FY2025
Does it pass the value tests?
Quality
33
- ○ROIC > 12% (5y avg)5y avg ROIC 7.4%
- ○ROE > 15% (5y avg)5y avg ROE 7.2%
- ○Stable operating marginsMargin volatility 5.9% (σ, 5y)
- ●Earnings convert to cashFCF / net income 168% (5y avg)
- ●Growing revenueRevenue CAGR 5y 30.1%
- ○Shrinking share countDiluted shares 35.7% over 5y
Value
40
- ○P/E below 15P/E 18.4
- ○EV/EBIT below 12EV/EBIT 19.1
- ●FCF yield above 6%FCF yield 6.1%
- ○Price below Graham NumberGraham Number $54.81
- ●P/B below 3P/B 2.1
Safety
100
- –Debt / equity below 0.5D/E n/a
- ●Debt payable in < 4 yrs of earningsNet debt $-0.5B
- –Interest coverage > 8xCoverage n/ax
- ●Current ratio > 1.5Current ratio 4.26
- ●Piotroski F-score ≥ 6F-score 8/9
Graham Defensive
57
- ●Adequate size (revenue > $2B)Revenue $2.9B
- ●Strong condition (current ratio ≥ 2)Current ratio 4.26
- ●Earnings stability (no loss, 10y)10 years of data
- ○Uninterrupted dividendsDividends paid every year on record
- ●Earnings growth ≥ 33% (10y, 3y avgs)EPS growth 54%
- ○Moderate P/E (≤ 15 on 3y avg EPS)P/E (3y avg) 37.7
- ○P/E × P/B ≤ 22.5Product 79.9
Valuation lab
What do you have to believe?
At $72.14, the market is pricing in about 2.3% annual free-cash-flow growth for the next decade (9% discount rate, 2.5% terminal growth).
Starting cash flow
Net debt −$526M · 134M shares · 5y revenue CAGR 30.1%
Intrinsic value
$262.06
Price
$72.14
Margin of safety
72%
What the price implies
The market is paying for 2.3% annual cash-flow growth for 10 years at a 9.0% discount rate.
Terminal value share
70% of the value sits beyond year 10. That means the answer depends mostly on the long-run assumptions.
Financial statements
A decade of the record.
USD millions · fiscal years · source: SEC 10-K XBRL
| Line item | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 564 | 636 | 713 | 785 | 789 | 958 | 1,023 | 1,568 | 2,519 | 2,939 |
| Gross profit | 429 | 486 | 554 | 605 | 572 | 719 | 759 | 1,020 | — | — |
| Operating income | 154 | 162 | 169 | 172 | 111 | 172 | 228 | 133 | 166 | 480 |
| Operating margin | 27.3% | 25.4% | 23.7% | 21.9% | 14.1% | 17.9% | 22.3% | 8.5% | 6.6% | 16.3% |
| Pre-tax income | 157 | 170 | 189 | 190 | 126 | 180 | 243 | 165 | 121 | 605 |
| Income tax | 53 | 63 | 32 | 35 | 24 | 31 | 53 | 43 | 18 | 67 |
| Net income | 104 | 107 | 156 | 155 | 102 | 149 | 190 | 123 | 103 | 538 |
| EPS (diluted) | 1.08 | 1.10 | 1.54 | 1.52 | 1.01 | 1.44 | 1.85 | 1.07 | 0.75 | 3.92 |
| Diluted shares | 96 | 98 | 101 | 102 | 101 | 104 | 103 | 115 | 138 | 137 |
Who owns it